Skip to main content
enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
2.410
+0.130 (5.70%)
At close: Nov 13, 2026, 4:00 PM EST
2.319
-0.091 (-3.78%)
After-hours: Nov 13, 2026, 7:58 PM EST

enGene Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Nov - Oct.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Net Income
-130.36-117.3-55.14-99.92-24.46-23.44
Depreciation & Amortization
0.720.510.320.180.240.27
Other Amortization
---0.92--
Loss (Gain) From Sale of Assets
--0.02---
Loss (Gain) From Sale of Investments
-1.79-3.07-0.23---
Stock-Based Compensation
17.369.655.323.450.120.44
Other Operating Activities
2.191.241.3371.144.347.79
Change in Accounts Payable
-0.184.940.470.37-0.20.11
Change in Other Net Operating Assets
8.875.39-2.390.122.23-1.44
Operating Cash Flow
-103.31-99.24-48.28-24.74-17.59-15.98
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Capital Expenditures
-0.69-1.49-0.93-0.32-0.15-0.25
Sale of Property, Plant & Equipment
-----0
Investment in Securities
-31.35-23.65-125.03---
Investing Cash Flow
-32.04-25.14-125.95-0.32-0.15-0.25

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Long-Term Debt Issued
--22.53829.48.03
Long-Term Debt Repaid
--0.7-9.45-4.73-1.01-0.96
Net Debt Issued (Repaid)
1.95-0.713.0633.2728.397.07
Issuance of Common Stock
151.792.22266.2556.940.010.01
Other Financing Activities
-9.99--13.58-4.06-0.44-0.14
Financing Cash Flow
143.751.52265.7286.1527.9722.53

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Foreign Exchange Rate Adjustments
0000-0.810.1
Net Cash Flow
8.4-122.8591.4861.099.426.39

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Free Cash Flow
-104-100.72-49.21-25.06-17.75-16.23
Free Cash Flow Growth
------
Free Cash Flow Per Share
-1.61-1.97-1.30-36.18-27.09-4.56
Levered Free Cash Flow
-60.85-60.38-32.23-16.07-10.75-
Unlevered Free Cash Flow
-58.93-58.51-30.48-13.89-9.86-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Cash Interest Paid
2.32.291.93-0.62-
Change in Working Capital
8.429.740.1-0.522.17-1.04
SEC Filings: 10-K · 10-Q